2004. CÀNCER. PROJECTES FINANÇATS

Dr Joaquin V. Arribas López

Anido J., Scaltriti M., Bech Serra JJ., Federico Rojo F., Baselga J. and Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234-3244 1. F. 10,492, 1 cuartil Biochemestry & Molecular Biology. (2006)

Pedersen K., PD Laos S., Ferrer-Ramón C., García-Castillo J., Parra-Palau J. LI, Scaltriti M., Baselga J., and Arribas J. Oncogenic Activity ofNatural HER2lsoforms Lacking the Extracellular Domain Depends on their Ability to Form Dimers Maintained by Disulphide Bonds (submitted) (2008)

Arribas, J., and Esselens, C.. ADAM17 as a Therapeutic Target in Multiple Diseases. Curr Pharm Des 15, 2319-2335. (2009)

Garcia-Castillo, J., Pedersen, K., Angelini, P.D., Bech-Serra, J.J., Colome, N., Cunningham, M.P., Parra Palau, J.L., Canals, F., Baselga, J., and Arribas, J. HER2 carboxy terminal fragments regulate cell migration and cortactin phosphorylation. J Biol Chem. (2009).

Pedersen, K., Angelini, P.D., Laos, S., Bach-Faig, A., Cunningham, M.P., Ferrer-Ramon, C., Luque-Garcia, A., Garcia-Castillo, J., Parra-Palau, J.L., Scaltriti, M., et al.. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 29, 3319-3331. (2009)

Dr Agustí Barnadas Molins

Pavón MA., León X., Sancho FJ., Téllez M., Céspedes MV., Lopez-Pousa A., Mangues MA., Quer M., Barnadas A., Parreño M., Mangues R. Gene expression signatures and molecular markers predict response in locally advanced head and neck squamous cell carcinoma (send) (2010)

Pavón MA., Parreño M., León X., Sancho FJ., Céspedes MV, Casanova I., Lopez-Pousa A., Mangues MA., Quer M., Barnadas A., Mangues R. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. Int J Cancer. 2008 Sep 1;123(5):1068-79.

Dr Jerónimo Blanco Fernández

Vilalta M., Dégano IR., Bagó J., Aguilar E., Gambhir SS., Rubio N., Blanco J.. Human adipose tissue derived mesenchymal stromal cells as vehicles for tumor bystander effect. A model based on bioluminescence imaging. J. Gene Ther. 2009. 16: 547-57.

Soler M. , Mancini F., Meca-Cortés O., Sánchez-Cid L., Rubio N., López-Fernández S., Lozano JJ., Blanco J., Fernández PL., Thomson TM.HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer. 2009. 125: 2565-75.

Dégano IR., Quintana L., Vilalta M., Horna D., Rubio N., Borrós S., Semino C., Blanco J.The effect of self-assembling peptide nanofiber scaffolds on mouse embryonic fibroblast implantation and proliferation.. Biomaterials. 2009. 30: 1156-65

Vilalta M., Jorgensen C., Dégano IR., Chernajovsky Y., Gould D., Noël D., Andrades JA. Becerra J., Rubio N., Blanco J. Dual luciferase labelling for non-invasive bioluminescence imaging of mesenchymal stromal cell chondrogenic differentiation in demineralized bone matrix scaffolds.. Biomaterials. 2009. 30:4986-95.

Vilalta M., Dégano IR., Bagó J., Gould D., Santos M., García-Arranz M., Ayats R., Fuster C., Chernajovsky Y., García-Olmo D., Rubio N., Blanco J. Biodistribution, long term survival and safety of human adipose tissue derived mesenchymal stem cells in nude mice by non-invasive bioluminescence imaging.. Stem Cells and Development. 2008.17: 993-1003.

Gyöngyösi M., Blanco J., Marian T., Trón L., Petneházy O., Petrasi Z., Hemetsberger R., Rodriguez J., Font G., Pavo IJ-, Kertész I-, Balkay L-, Pavo N., Posa A., Emri M., Galuska L., Kraitchman DL.., Wojta J., Huber K., Glogar D. Serial Noninvasive In Vivo Positron Emission Tomographic Tracking of Stem Cells Modified for Transgene Reporter Gene Expression Percutaneously Intramyocardially Injected Autologous Porcine Mesenchymal Stem Cells Modified for Transgene Reporter Gene Expression. Circulation: Cardiovasc Imaging. 2008 1: 94-103.

Román I., Vilalta M., Rodriguez J., Matthies AM., Srouji S., Livne E., Hubbell JA., Rubio N., Blanco J. Analysis of progenitor cell-scaffold combinations by in vivo non-invasive photonic imaging.. Biomaterials. 2007. 28: 2718-28.

Dégano IR., Vilalta M., Bagó JR., Matthies AM., Hubbell JA., Dimitriou H., Bianco P., Rubio N., Blanco J. Bioluminescence imaging of calvarial bone repair using bone marrow and adipose tissue-derived mesenchymal stem cells. Biomaterials. 2008. 29: 427-37.

Dr Francesc Bosch Albareda

Muntañola A., Bosch F., Arguis P., Arellano-Rodrigo E., Ayuso C., Giné E., Crespo M., Abrisqueta P., Moreno C., Coba F., López-Guillermo A., Montserrat E. Abdominal computed tomography predicts progression in patients with Rai stage O chronic lymphocytic leukemia. Journal of Clinical Oncology Año: 2007 Vol.: 12 Págs.: 1576-80. specialitat (ISI): Oncology Indice de Impacto (ISI): 13,598.

Ferrer A., Salaverria I., Bosch F., Villamor N., Rozman M., Bea S., Giné E., López-Guillermo A., Campo E., Montserrat E. Leukemic involvement is a common feature in mantle celllymphoma. Cancer Año: 2007 Vol.: 109 Págs.: ):2473-80. Especialidad ISI Oncology. Indice de Impacto (ISI): 4,58

Wiestner A., Tehrani M., Chiorazzi M., Wright G., Gibellini F., Nakayama K., Liu H., Rosenwald A., Muller-Hermelink HK., Ott G., Chan WC., Greiner TC., Weisenburger DD., Vose J., Armitage JO., Gascoyne RD., Connors JM., Campo E., Montserrat E., Bosch F., Smeland EB., Kvaloy S., Holte H., Delabie J., Fisher RI., Grogan TM., Miller TP., Wilson WH., Jaffe ES., Staudt LM. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. BLOOD Año: 2007 Vol.: 109 Págs.: 4599-606 Especialidad (ISI): Oncology Indice de Impacto (ISI): 10,370

Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., Belhoul L., Stella S., Stavroyianni N., Crespo M., Hadzidimitriou A., Sutton L., Bosch F., Laoutaris N., Anagnostopoulos A., Montserrat E., Fassas A., Dighiero G., Caligaris-Cappio F., Merle-Beral H., Ghia P.,Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. BLOOD Año: 2007 Vol.: 109 Págs.: 259-70 Especialidad (ISI): ONCOLOGY Indice de Impacto (ISI): 10,370

Bosch F., Muntanola A., Gine E., Carrio A., Villamor N., Moreno C., Crespo M., Montserrat E. Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom. Año: 2006 Vol.: 70 Págs.: 214-7. pecialidad (ISI): ONCOLOGY Indice de Impacto (ISI): 2.065

Crespo M., Villamor N., Gine E., Muntanola A., Colomer D., Marafioti T., Jones M., Camos M., Campo E., Montserrat E., Bosch F. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clinical Cancer Research Año: 2006 Vol.: 12 Págs.: 726-734 Especialidad (ISI): Oncology Indice de Impacto (ISI): 6,177

Bosch F., Abrisqueta P.; Villamor N.; Terol MJ.; González-Barca E.; Ferra F.; Gonzalez Diaz M.; Abella E.; Delgado J.; Carbonell F.; Garcia-Marco JA.; Escoda L.; Ferrer S.; Monzó E.; González Y.; Estany C.; Jarque I.; Salamero O.; Muntañola A.; Montserrat E. Rituximab, Fludarabine,Cyclophosphamide, and Mitoxantrone (R-FCM) a New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leucemia.. J Clin Oncol, 2009 (in press).

Abrisqueta P., Villamor N., Crespo M., Muntañola A., Navarro A., Codony C., López C., Salamero O., Calpe E., Gomes MJ., Camós M., Gutiérrez-García G., Giné E., López-Guillermo A., Rozman C., Montserrat E., Bosch F.. Biological analysis and prognostic significance of the proliferative cellular compartment in chronic lymphocytic leukemia. Blood (2010) (send)

Calpe E., Codony C., Crespo M., Baptista MJ., Abrisqueta P., Montserrat E., Bosch F. Increased activation and migration upon ectopic expression of ZAP-70 expressing in tumoral B cells. Blood (2010) (send)

Dr Francesc Xavier Bosch José

Dr. Chris J. L. M. Meijer

Dr. Massimo Tommasino

Castellsagué X., Klaustermeier J., Carrilho C., Albero G., Sacarlal J., Quint W. et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. Int J Cancer. 122, 1901–1904 (2008)

Odida M., de Sanjosé S., Quint W., Bosch FX., Klaustermeier J. and Weiderpass E. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infectious Diseases. 8:85 (2008).

Usubütün A., Alemany L., Kücükali T., Ayhan A., Yüce K., de Sanjosé S., et al. Human Papillomavirus Types in Invasive Cervical Cancer Specimens From Turkey. Int J Gynecol Pathol. 28 (6), 541-548 (2009).

Sánchez GI. et al. Development and clinical evaluation of a highly sensitive and specific PCR-Reverse Hybridization Assay for detection and identification of Human Papillomavirus type 16 variants (manuscript in preparation)

De Sanjosé S. et al. Human Papillomavirus genotype attribution in invasive cervical cancer: 10,575 cases. The International ICO Survey. (manuscript in preparation)

Manuscript regarding the description of the HPV 33-45 variants identified in the case-control study. (manuscript in preparation)

Manuscripts describing the HPV 16-18 variants found in adenocarcinomas of the cervix from the paraffin-embedded series. (manuscript in preparation)

And also from HPV 58 variants in paraffin SCC of the cervix. (manuscript in preparation)

Dr Miquell Coll Capella

Boer DR., Canals A., Coll M. DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes. Dalton Transactions (3), 399 - 414. (2008)

Boer DR., Ruíz-Masó JA., López-Blanco JR., Blanco AG., Vives-Llàcer M., Chacón P., Usón I., Gomis-Rüth FX., Espinosa M., Llorca O., del Solar G., Coll, M. Plasmid replication initiator RepB forms a hexamer reminiscent of ring helicases and has mobile nuclease domains. EMBO J. 28, 1666-1678. (2009)

Canals A., Coll M. Cloning, expression, purification and crystallization of the Rho transcription termination factor from Thermotoga maritima. Protein Expression and Purification, 65, 174-178. (2009)

Boer DR., Kerckhoffs JM., Parajo Y., Pascu M., Usón I., Lincoln P., Hannon MJ., Coll, M. Towards functionable DNA frames: Self-assembly of functionalizable two-component 3D DNA arrays through the induced formation of DNA three-way-junction branch points by supramolecular cylinders. Angew. Chem. Int. Ed. Engl. 49, 2336-9. (2010)

Canals A., Usón I.,Coll M. The structure of RNA-free Rho termination factor indicates a dynamic mechanism of transcript capture. (2010) J. Mol. Biol (in press)

Dra Miriam Cuatrecasas Freixas

Cuatrecasas M., Landolfi S., Espin E., Tabernero J., Ramon y Cajal S. Valor del ganglio linfático centinela en el estadiaje del carcinoma de colon. Estudio comparativo inmunohistoquímico y patológico de re-estadificación ganglionar en pacientes en estadios I and II. XXIV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la Academia Internacional de Patología. XIX Congreso de la Sociedad Española de Citología. Sevilla, (2009). Revista Española de Patología 2009; 42 Suplemento 1 : página 90.

Cuatrecasas M., Landolfi S., Espin E., Pons C., Ramon y Cajal S., Tabernero J Manuscript in preparation: Does sentinel colonic lymph node improve staging accuracy? A comparative immunohistochemical and pathologic analysis of nodal upstaging in stage I and II patients.. Journal of Surgical Oncology.

Dr Carme de Bolós Pi

Dr Pere Clapés Saborit

Dr Rosa Peracaula Miró

Castillo JA., Calveras J., Casas J., Mitjans M., Vinardell MP., Parella T., Inoue T., Sprenger GA., Joglar J., Clapes P. Fructose-6-phosphate Aldolase in Organic Synthesis: Preparation of D-Fagomine, N-Alkylated Derivatives, and Preliminary Biological Assays. Org. Lett. 2006, 8, (26), 6067-6070.

Mejías-Luque R., López-Ferrer A., Garrido M., Fabra A., de Bolós C.. Changes in the invasive and metastasic capacities of HT-29/M3 cells induced by the expression of FUT1. Cancer Sci. 2007, 98:1000-1005.

Calveras J, Casas J., Parella T., Joglar J., Clapés P. Chemoenzymatic Synthesis and Inhibitory Activities of Hyacinthacines A1 and A2 Stereoisomers. Adv. Synth. Catal. 2007, 349, (10), 1661-1666.

Gutierrez ML., Garrabou X., Agosta E., Servi S., Parella T, Joglar J., Clapés P. Serine Hydroxymethyl Transferase from Streptococcus thermophilus and L-threonine Aldolase from Escherichia coli as Stereocomplementary Biocatalysts for the Synthesis of beta-Hydroxy-alfa,omega-diamino Acid Derivatives. Chem. Eur. J. 2008, 14, (15), 4647-4656.

Mejías-Luque R., Peiró S., Vincent A., Van Seuningen I., de Bolós C. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. BBA-Molecular Cell Research. 2008; 1783: 1728-1736.

Concia AL., Lozano C., Castillo JA., Parella T., Joglar J., Clapés P. D-Fructose-6-phosphate Aldolase in Organic Synthesis (II): Cascade chemical-enzymatic preparation of sugar related polyhydroxylated compounds. Chem. Eur. J. 2009, 15, 3808-3816.

Garrabou X,. Castillo JA., Guérard-Hélaine C., Parella T., Joglar J., Lemaire M., Clapés P. Asymmetric self- and cross-aldol reaction of glycolaldehyde catalyzed by D-fructose-6-phosphate aldolase. Angew. Chem. Int. Ed. 2009, 48, 5521-5525.

Calveras J., Egido-Gabás M., Gómez L., Casas J., Parella T., Joglar J., Bujons J., Clapés P. Dihydroxyacetone phosphate aldolase-catalyzed synthesis of structurally diverse polyhydroxylated pyrrolidine derivatives and evaluation of their glycosidase inhibitory properties. Chem. Eur. J. 2009, 15, 7310-7328.

Mejías-Luque R., de Bolós C. Inflammatory cytokines pathways as potential therapeutic target for gastric cancer. Current Cancer Therapy Reviews. 2009; 5: 178-187.

Padró M., Castillo J., Gómez L., Joglar J., Clapés P., de Bolós C. Cytotoxicity and enzymatic activity inhibition in cell lines treated with novel iminosugar derivatives. Glycoconjugate J. 2010;27:277-285.

Mejias-Luque R., Lindén SK., Garrido M., Tye H., Najdovska M., Jenkins BJ., Iglesias M., Ernst M., de Bolós C. Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors. Oncogene (2010)

Pérez-Garay M., Arteta B., Pagès L., de Llorens R., de Bolòs C., Vidal-Vanaclocha F., Peracaula R. Alpha-2,3-sialyltransferase ST3Gal III overexpression contributes to pancreatic cancer metastasis by increasing E-Selectin adhesion and cell motility. Glycobiology (submitted).

Dra Silvia de Sanjosé Llongueras

Nieters A., de Sanjosé S., Skibola FK., Becker N., Maynadié M., Benavente Y., Foretova L., Cocco PL., Staines A., Boffetta P., Brennan P.. TNFRSF5 and TNFSF5 gene variants and the risk of lymphoma in EpiLymph. (summitted for publication)

Conde L., Halperin E., Brown KM., Smedby KE., Rothman N., Nieters A., Slager SL., Brooks-Wilson A., Agana L., Akers NK., Riby J., Adami HO., Chang ET., Darabi H., Glimelius B., Hjalgrim H., Humphreys K., Liu G., Low HK., Melbye M., Cozen W., Davis S., Hartge P., Morton LM., Schenk M., Wang SS., Armstrong B., Kricker A., Milliken S., Purdue MP., Vajdic CM., Boyle P., Lan Q., Zahm S., Zhang Y., Zheng T., Becker K.., Benavente Y., Boffetta P., Brennan P., Butterbach K., Cocco P., Foretova L., Maynadié M., de Sanjosé S., Staines A., Spinelli JJ., Achenbach SJ., Call TJ., Camp NJ., Caporaso NE, Cerhan JR., Cunningham JM., Goldin LR., Hanson CA., Kay NE., Lanasa MC., Leis JF., Marti GE., Rabe KG., Rassenti L., Spector LG., Strom SS., Vachon CM., Weinberg JB., Holly EA., Chanock S., Smith MT., Bracci PM., Skibola CF. Genome-wide association study identifies novel HLA-DQB1 risk alleles specific to follicular lymphoma (summitted for publication)

Casabonne D., Reina O., Benavente Y., Becker K., Maynadi M., Foretova L., Cocco PL., González A., Nieters A., Middeldorp JA., De Sanjose S. Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP-9) and tumour protein 73 (p73) interact with Epstein Barr virus in chronic lymphocytic leukemia: results from the European case-control study. EPILYMPH. (summitted for publication)

Dr Luciano Di Croce

Buschbeck M., Uribesalgo I., Ledl A., Gutierrez A., Minucci S., Muller S., and Di Croce L. PML4 induces differentiation by Myc destabilization. Oncogene, 26, 3415-3422. (2007)

Villa R., Pasini D., Gutierrez A., Viré E., Nomdedeu JF., Jenuwein T., Pelicci PG., Minucci S., Fuks F., Helin K., and Di Croce L. Role of the Polycomb repressive complex 2 in leukemia. Cancer Cell, 11, 513-525. (2007)

Carnicer MJ., Lasa A., Buschbeck M., Serrano E., Carricondo M., Brunet S., Aventin A., Sierra J., Di Croce L., and Nomdedeu JF. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML). Ann Hematol, 87, 819-27-81. (2008)

Morey L, Brenner C, Fazi F, Villa R, Gutierrez A, Buschbeck M, Nervi C, Minucci S, Fuks F, and Di Croce L. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 28, 5912-23. (2008)

Buschbeck M, Uribesalgo I, Wibowo I, Rué P, Martin D, Gutierrez A, Morey L, Guigó R, López-Schier H, and Di Croce L. The histone variant macroH2A is an epigenetic regulator of key developmental genes. Nature Struct Mol Biol. 16,1074-79. (2009)

Dra Mireia Duñach Masjuan

Dr Josep Baulida Estadella

Dr Antoni Riera Escalé

Ramón R., Loubat J., Alonso M., Ginesta X., Riquel A., García de Herreros A., Duñach M., Baulida J. , Riera A. Enantioselective Synthesis of Tetrahydroisoquinoline-3-carboxylic Acids (Tic) with Quinone Fragments. Study of their cell apoptosis regulation behaviour. submitted to Journal of Medicinal Chemistry (currently under review)

Dr Lluís Espinosa Blay

Dr Marty W. Mayo

Fernández-Majada V., Pujadas J., Vilardell F., Capella G., Mayo MW., Sigas A., Espinosa L. Aberrant cytoplasmic localization of N-CoR in colorectal tumors. Cell Cycle. 2007 May;6(14):1748-52.

Fernández-Majada V., Aguilera C., Villanueva A., Vilardell F., Robert-Moreno A., Ay tés A., Real FX., Capella G., Mayo MW., Espinosa L., Sigas A. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA. 2007 Jan 2;104(1):276-81. PNAS published online Dec 26, 2006;

Dr Joan Ignasi Esteban Mur

Zabaleta A., Arribillaga L., Llopiz D., Dotor J., Lasarte JJ., Prieto J., Borrás-Cuesta F., Esteban JI., Quer J., Vayreda F., Sarobe P. Induction of potent and long lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral research 2007;74:25-35 . Factor d’impacte (FI) 2.878.

Quer J., Esteban JI., Sánchez JM., Otero T., Rius C., Coll M., Cubero M., Moreno G., Gonzalez A., Vaque J., Esteban R., Campins M., Pañella H., Guardia J., Martell M. Nosocomial transmission of HCV during contrast-enhanced computed tomography scanning. European Journal of gastroenterology & hepatology 2008; 20(1):73-78.I.FI: 1.895.

Cubero M., Esteban JI., Otero T., Sauleda S., Bes M., Esteban R., Guardia J., Quer J. Naturally occurring NS3 protease-inhibitor resistant-mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370 (2):237-245. FI:3.525

Diaz O., Cubero M., Trabaud MA., Quer J., Icard V., Esteban JI., Lotteau V., André P. Transmission of low density hepatitis C viral particles during sexually transmitted acute resolving infection. Journal Medical Virology; 2008; 80:242-246. FI:2.779

Esteban JI., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology; 2008; 48(1):148-162. FI:6.073.

Fernandez-Fernandez A., Rosales C., Lopez-Nieva P., Graña O., Ballestar E., Ropero S., Espada J., Almeida S., Lujambio A., Fraga MF., Pino I., Javierre B., Acquadro F., Steenbergen R., Meijer CJ., Pineau P., Dejean A., Quer J., Buti M., Esteban JI., Allende H., Rodriguez-Frias F., Lloveras B., Castellsague X., Minarovits J., Capello D., Gaidano G., Cigudosa JC., Gomez-Lopez G., Pisano DG., Valencia A., Piris MA., Bosch FX., Cahir-McFarland E., Kieff E., Esteller M. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009 Mar;19(3):438-51. FI:11,244

Bes M., Esteban JI., Casamitjana N., Piron M., Quer J., Cubero M., Puig LL., Guardia J., Sauleda S. Hepatitis C virus (HCV)-specific T-cell responses among RIBA3–indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion. 2009 Jul;49(7):1296-305. FI: 3,374.

Bes M., Sauleda S., Cerezo, B., Casamitjana N., Piron M., Quer J., Cubero M. ,Puig L., Guardia J., Esteban JL. Election, expansion and functional restoration of NS3-specific CD4 T cells in patients with HCV persistent infection Hepatology. (in preparation)

Dr David Gallardo Giralt

Hoyos M., Guardia R., Oriol A., Rodríguez-Luaces M., Hermosilla M., Ribera JM., Font L., Pujal JM, Pérez A., Gallardo D. Sobreexpresión de WT1 posquimioterapia de inducción como marcador pronóstico en leucemia aguda mieloblástica. XLIX Reunión Nacional de la Asociación Española de Hematología y Hemoterapia (AEHH). Haematologica 2007; 92 (Extr 2): pag. 21.

Dra M. Àngels Ginès Gibert

Rosell,.Ginès A., Serra M., Gámez C. Estadifiación mediastínica del cáncer de pulmón en el siglo XXI: un reto de carácter multidisciplinario. Rosell. Med Clin 2008; 130:415-22.

Sendino O., Alonso-Espinaco V., Pellisé M., Solé M., Muñoz J., Fernández-Esparrach G., Colomo Ll., Llach J., Castells A., Castellví-Bel., Ginès A. Análisi molecular de l’EGFR i K-RAS en postres obtingudes per punció aspirativa amb agulla fina guiada per ecoendoscòpia en pacients amb càncer de pulmó de cèl•lules no petites. XVIII Congrés de la Societat Catalana de Digestologia. Blanes. (2009). Suppl Annals de Medicina 2009; 92:S1-64

Sendino O., Alonso-Espinaco V., Pellisé M., Solé M., Muñoz J., Fernández-Esparrach G., Colomo Ll., Llach J., Castells A., Castellví-Bel S., Ginès A. Análisis molecular de EGFR y K-RAS en muestras obtenidas por punción aspirativa con aguja fina guiada por ecoendoscopia (USE-PAAF) en pacientes con cáncer de pulmón de células no pequeñas (CPCNP). XII Reunión Nacional Anual de la AEG. Madrid, (2009). Gastroenterol Hepatol 2009;32:197)

Sendino O., Alonso-Espinaco V., Pellisé M., Solé M., Muñoz J., Fernández-Esparrach G, Colomo Ll., Llach J, Castells A., Castellví-Bel S., Ginès A. Análisis molecular de EGFR y K-RAS en muestras obtenidas por punción aspirativa con aguja fina guiada por ecoendoscopia (USE-PAAF) en pacientes con cáncer de pulmón de células no pequeñas (CPCNP). 42º Congreso Nacional de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). (2009) Arch Bronconeumol 2009; 45:116

Ginès A., Sendino O., Belda J., Solé M., Fernández-Esparrach G., Martínez E, Pellisé M., Colomo Ll., Bordas JM., Llach J. Pución aspirativa con aguja fina guiada por ecoendoscopia (USE-PAAF) en la reestadificación mediastínica tras tratameinto neoadyuvante en pacientes con cáncer de pulmón de células no pequelas (CPCNP). Resultados preliminares. 42º Congreso Nacional de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). (2009) Arch Bronconeumol 2009; 45:135.

Ginès A., Sendino O., Belda J., Solé M., Fernández-Esparrach G., Martínez E., Pellisé M., Colomo Ll., Bordas JM., Llach J. Endoscopic Ultrasonography-Guided Fine Needle Aspiration (EUS-FNA) in Mediastinal Restaging after Neoadjuvant Therapy in patients with Non-Small Cell Lung Cancer (NSCLC). Preliminary Results. Digestive Disease Week Chicago, (2009) Gastrointest Endosc 2009;69:AB329-40

Sendino O., Alonso-Espinaco V., Pellisé M., Solé M., Muñoz J., Fernández-Esparrach G., Colomo Ll., Llach J., Castells A., Castellví-Bel S., Ginès A. Molecular analysis of EGFR and K-RAS in samples obtained by endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) in patients with non-small cell lung cancer (NSCLC) . Digestive Disease Week (2009). Gastrointest Endosc 2009;69:AB335

Dr Francesc Gudiol Munté

Calatayud L., Arnan M., Liñares J., Dominguez MA., Gudiol C., Carratalà J., Batlle M., . Ribera JM., Gudiol F. Prospective study of fecal colonization by extended-spectrum β-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob. Agents Chemother. 2008. 52:4187-4190.

Gudiol C., Calatayud L., Garcia-Vidal C., Lora-Tamayo J., Cisnal M., Duarte R., Arnan M., Marin M., Carratalà J., Gudiol F. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010 Feb;65(2):333-41.

Arnan M., Gudiol C., Calatayud L., Liñares J., Domínguez MA., Batlle M., Ribera JM., Carratalà J., Gudiol F. Risk Factors for, and Clinical Relevance of, Fecal Extended-Spectrum b-Lactamase producing Escherichia coli (ESBL-EC) Carriage in Neutropenic Patients with Hematological Malignancies. (Sent for publication to Journal of Antimicrobial Chemotherapy)

Dra Pilar Lauzurica Gómez

Vega-ramos J., Alari Pahissa E., Esplugues E and P Lauzurica. Treatment of CD69+ leukemia with anti-CD69 depleting antibodies. (2010). (submitted)

Alari Pahissa E., Vega-ramos J., Albentosa A., Villadangos J. and P. Lauzurica Stimulatory role of CD69 in the antigen unspecific anti-tumour response. (2010). (in preparation)

Dr Matilde Esther Lleonart Pajarin

Dr Zhao-Qi Wang

Dr David Hugh Beach

Lleonart ME., Maruyama T., Kondoh H. Challenges and oportunities for cancer therapy based on senescence induction. Invited review, Proteomics (manuscript in press)

Artero-Castro A., Castellvi J., García A., Hernández J., Ramón y Cajal S., LLeonart M. Expression of the ribosomal proteins Rplp0, Rplp1 and Rplp2 in gynecological tumors (second review Human Pathology).

Lleonart ME., Borgoff V., Bishop C., Fessart D., Bergin AM., Beach DH. Multiple microRNAs bypass ras-induced senescence. Oncogene, 2010, 25 Jan.

Lleonart ME. Cold-inducible RNA binding proteins: A new generation of proto-oncogenes. BBA Rev Cancer, 2010, 1805: 43-52.

López L., Armengol G., Pons B., Argelaguet E., LLeonart ME., Hernández J., Torres I., Ramon y Cajal S. Regulation of replicative and stress-induced senescence by RSK4, which is downregulated in human tumors. A potencial hallmark factor of senescence mediating pathways. Clinical Cancer Research, 2009, 15(14):4546-53.

Artero-Castro A., Kondoh H., Fernández-Marcos P., Serrano M., Ramón y Cajal S, LLeonart ME. Rplp1 bypasses replicative senescence and contributes to transformation. Experimental Cell Research, 2009, 315(8):1372-83

Artero-Castro A., Callejas FB., Castellvi J., Kondoh H., Carnero A., Fernández-Marcos PJ., Serrano M., Ramón y Cajal S., LLeonart M3. CIRP modulates life-span in primary MEFs. Molecular and Cellular Biology, 2009, 29(7):1855-68.

Lleonart ME., Artero-Castro A., Kondoh H. Senescence induction; a possible cancer therapy. Molecular Cancer. 2009, 8;8(1):3.

Kondoh H., Lleonart ME., Nakashima Y., Maruyama T., Yokode M., Tanaka M, Bernard D., Gil J. Essential metabolic characteristics in murine ES and primary cells to bypass senescence. Invited review, Medical Hypotheses and Research, 2008, 4, 29-36.

Leal JF., Fominaya J., Cascón A., Guijarro MV., Blanco-Aparicio C., Lleonart M., Castro ME., Ramon Y Cajal S., Robledo M., Beach DH., Carnero A. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene, 2008, Mar 27;27(14): 1961-70.

Kondoh H., Maruyama T., Lleonart M. Senescence as a target for cancer therapy. Invited review. Open Pathology, 2008, Vol. 2: 57-62.

Castro ME., Ferrer I., Cascón A., Guijarro MV., Lleonart ME., Cajal SR., Leal JF., Robledo M., Carnero A. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis, 2008 Mar; 29(3): 491-9.

Castro ME., Leal JF., Lleonart ME., Ramon y Cajal S., Carnero A. Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis, 2008 Jul;29(7):1343-50.

Leal JF., Blanco-Aparicio .C, Ferrer I., Hernández-Losa J., Ramón y Cajal S., Carnero A., LLeonart ME. S-Adenosyl homocytein hydrolase downregulation contributes to tumorigenesis. Carcinogenesis, 2008 29(7): 2089-95.

Guijarro MV., Leal JF., Blanco-Aparicio C., Alonso S., Fominaya J., Lleonart ME., Castellvi J., Ramon y Cajal S., Carnero A. MAP17 enhances the malignant behaviour of tumor cells through ROS increase. Carcinogenesis, 2007 Oct;28(10):2096-104.

Guijarro MV., Leal JF., Fominaya J., Blanco-Aparicio C., Alonso S., Lleonart ME., Castellvi J., Ruiz L., Ramon y Cajal S., Carnero A. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis, 2007 Aug;28(8):1646-52.

Lleonart ME., Kondoh H., Nakashima Y., Yokode M., Tanaka M., Bernard D., Gil J., Beach D. A High Glycolytic Flux Supports the Proliferative Potential of Murine Embryonic Stem cells. Antioxidant Redox Signaling 2007 Mar;9(3):293-9.

Kondoh H., Lleonart ME., Bernard D., Gil J. Protection from oxidative stress by enhanced glycolisis, a possible mechanism of cellular immortalisation. Histology & Histopathology, 2007 Vol. 22(1): 85-90.

Dr Núria Malats Riera

Dr María Luz Calle Rosingana

Dr Javier Benítez Ortiz

Murta-Nascimento C., Real FX., García-Closas M., Rothman N., Lloreta J., Vellalta G., Tardón A., Carrato A., Serra C., García-Closas R., Silverman DT., Dosemeci, Kogevinas M., Malats N., on behalf of the EPICURO/Spanish Bladder Cancer Study investigators. Genetic variation in N-acetyl transferases and glutathione S-transferases and bladder cancer prognosis (submited to publication)

Lorente B., Medina I., Morcillo C., Sangrós R., Alegre J., Pita G.,Vellalta G., Malats N., Pisano DG., Dopazo J., Navarro A. SYSNPs (Select Your SNPs): a web tool for automatic/massive selection of SNPs (submited to publication)

Calle ML., Urrea V., Malats N., Van Steen K. MB-MDR: Model-Based Multifactor Dimensionality Reduction for detecting interactions in highdimensional genomic data (submited to publication)

Murta-Nascimento C, Schmitz-Dräger B, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 2007;25:285-95.

Murta-Nascimento C. et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev 2007;16:1595-600.

Real FX., Malats N. Bladder cancer and apoptosis: matters of life and death. Lancet Oncol 2007;8:91-2.

Calle ML., Sánchez-Espigares JA. Árboles de Clasificación y Regresión en la Investigación Biomédica. Medicina Clínica 2007;129:702-706.

Calle ML., Urrea V., Vellalta G., Malats N., Van Steen K. Improving strategies for detecting genetic patterns of disease susceptibility in association studies. Statistics in Medicine 2008; 27:6532-6546.

Figueroa JD., Malats N., García-Closas M., Real FX., Silverman D., Kogevinas M., Chanock S., Welch R, Dosemeci M., Lan Q., Tardón A., Serra C., Carrato A., García-Closas R., Castaño-Vinyals G., Rothman N. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008;10:1955-62.

Lotan Y., Svatek RS., Malats N. Screening for bladder cancer: a perspective. World J Urol 2008;26:13-8.

Malats N. Genetic epidemiology of bladder cancer: scaling up in the identification of low penetrance genetic markers of bladder cancer risk and progression. WHO Bladder Cancer report. Scand J Urol Nephrol Suppl. 2008;218:131-40.

Moore LE., Pfeiffer RM., Poscablo C., Feal RX., Kogevinas M., Silverman D., García-Closas R., Chanock S., Tardón A., Serra C., Carrato A., Dosemeci M., García-Closas M., Esteller M., Fraga M., Rothman N., Malats N. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case–control study. Lancet Oncol 2008;9:359-66.

Castillejo A., Rothman N., Murta-Nascimento C., Malats N., García-Closas M., Gómez-Martínez A., Lloreta J., Tardón A., Serra C., García-Closas R., Chanock S., Silverman DT., Dosemeci M., Kogevinas M., Carrato A., Soto JL., Real FX. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 2009;124:608-13.

Malats N., Real FX. Editorial Comment on: FGFR3 Mutations indicate better survival in invasive upper Urinary tract and bladder tumours. Eur Urol 2009;55:658.

Stern MC., Lin J., Figueroa JD., Kelsey KT., Kiltie AE., Yuan JM., Matullo G., Fletcher T., Benhamou S., Taylor JA., Placidi D., Zhang ZF., Steineck G., Rothman N., Kogevinas M., Silverman D., Malats N., Chanock S., Wu X., Karagas MR., Andrew AS., Nelson HH., Bishop DT., Sak SC., Choudhury A., Barrett JH., Elliot F., Corral R., Joshi AD., Gago-Dominguez M., Cortessis VK., Xiang YB., Gao YT., Vineis P., Sacerdote C., Guarrera S., Polidoro S., Allione A., Gurzau E., Koppova K., Kumar R., Rudnai P., Porru S., Carta A., Campagna M., Arici C., Park SS., Garcia-Closas M; International Consortium of Bladder Cancer. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res 2009;69:6857-64.

Villanueva CM., Silverman DT., Murta-Nascimento C., Malats N., Garcia-Closas M., Castro F., Tardon A., Garcia-Closas R., Serra C., Carrato A., Rothman N., Real FX., Dosemeci M., Kogevinas M. Coffee consumption, genetic susceptibility and bladder cancer risk. Cancer Causes Control 2009;20:121-7.

Guey LT., García-Closas M., Murta-Nascimento C., Lloreta J., Palencia L., Kogevinas M., Rothman N., Vellalta G., Calle ML., Marenne G., Tardón A., Carrato A., García-Closas R., Serra C., Silverman D.T, Chanock S., Real FX., Malats N. EPICURO/Spanish Bladder Cancer Study investigators. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 2010;57:283-92.

Malats N., Vellalta G., García-Closas M., Murta-Nascimento C., Calle M., Urrea V., Tardón A., Carrato A., Serra C., García-Closas R., Silverman D., Dosemeci M., Real FX ., Rothman N. Specific patterns of inflammatory polymorphisms are associated with bladder cancer risk. A large scale analysis of the Spanish Bladder Cancer Study. (in preparation)

Murta-Nascimento C., Vellalta G., Calle M., Urrea V., García-Closas M., Tardón A., Carrato A., Amorós A., Serra C., García-Closas R., Silverman D., Dosemeci M., Kogevinas M., Rothman N., Real FX., Malats N. Polymorphisms in inflammatory genes prognosticate bladder cancer outcome (in preparation)

Murta-Nascimento C., Novoa A., Porta N., Calle M., Amoros A., Vellalta G., Urrea V., García-Closas M., Tardón A., Carrato A., Amorós A., Serra C., García-Closas R., Silverman D., Dosemeci M., Rothman N., Kogevinas M., Real FX., Malats N. Is tobacco and independent prognostic marker for bladder cancer outcome? A time-dependent variable analysis (in preparation)

Dr Xavier Matias-Guiu Guia

Dr Miguel Abal Posada

Dr Jaime Prat Díaz de Losada

Dr José Palacios Calvo

Monge M., Colas E., Doll A., Gil-Moreno A., Castellvi J., Diaz B., Gonzalez M., Lopez-Lopez R., Xercavins J., Carreras R., Alameda F., Canals F., Gabrielli F., Reventos J., Abal M. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis, 2009; 30:1288-97

Monge M., Doll A., Colas E., Gil-Moreno A., Castellvi J., Garcia A., Colome N., Perez-Benavente A., Pedrola N., Lopez-Lopez R., Dolcet X., Ramon y Cajal S., Xercavins J., Matias-Guiu X., Canals F., Reventos J., Abal M. Proteomic approach to endometrial carcinoma invasion front. Journal of Proteome Research, 2009; 8:4676-84.

Doll A., Gonzalez M., Abal M., Llaurado M., Rigau M., Colas E., Monge M., Xercavins J., Capella G., Diaz B., Gil-Moreno A., Alameda F., Reventos J. An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. International Journal of Cancer, 2009; 125:257-63.

Doll A., Abal M., Rigau M., Monge M., Gonzalez M., Demajo S., Colás E., Llauradó M., Alazzouzi H., Planaguma J., Lohmann MA., Garcia J., Castellvi S., Cajal JR., Gil-Moreno A., Xercavins J., Alameda F., Reventos J. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008; 108:221-9.

Monge M., Colas E., Doll A., Gonzalez M., Gil-Moreno A., Planaguma J., Quiles M., Arbos MA., Garcia A., Castellvi J., Llaurado M., Rigau M., Alazzouzi H., Xercavins J., Alameda F., Reventos J., Abal M. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res. 2007; 67:6753-9.

Montserrat N., Llobet D., Dolcet X., Pons C., Pena J., Franci C., Matias-Guiu X., Prat J.: Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. (in preparation).

Catasus L., Pons C., Pena J., Espinosa I., Prat J. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol 2010 (in press).

Catasus L., Gallardo A., Cuatrecasas M., Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22:522-9.

Turbiner J., Moreno-Bueno G., Dahiya S., Sánchez-Estevez C., Hardisson D., Prat J., Oliva E., Palacios J. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol 2008;21:925-36.

Velasco A., Bussaglia E., Pallares J., Dolcet X., Llobet D., Encinas M., Llecha N., Palacios J., Prat J., Matias-Guiu X .PIK3CA gene mutations in endometrial carcinoma. Human Pathol 2006 37:1465-72

Dolcet X., Llobet D., Encinas M., Pallares J., Cabero A., Schoenenberger JA., Comella JX., Matias-Guiu X. Proteasome inhibitors induce death but activate NF-KB on endometrial carcinoma cell lines and primary culture explants. Journal of Biological Chemistry 2006 281:22118-30

Llobet D., Eritja N., Encinas M., Sorolla A., Yeramian A., Schoenenberger JA., Llombart-Cussac A,. Marti RM., Matias-Guiu X., Dolcet X. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs. 2008 19:115-24.

Llobet D., Eritja N., Encinas M., Llecha N., Yeramian A., Pallares J., Sorolla A., Gonzalez-Tallada FJ., Matias-Guiu X., Dolcet X. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene. 2008 27:2513-2524

Pallares J., Velasco A., Eritja N., Santacana M., Dolcet X., Cuatrecasas M., Palomar-Asenjo V., Catasus L., Prat J., Matias-Guiu X: Promoter hypermethylation and reduced expression of RASF1A are frequent molecular alterations of endometrial carcinoma. Modern Pathol 2008 2008 21:691-9

Pallares J., Llobet D., Santacana M., Eritja N., Velasco A., Cuevas D., Lopez S., Palomar-Asenjo V., Yeramian A., Dolcet X., Matias-Guiu X. CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol. 2009 174:287-96.

Llobet D., Eritja N., Yeramian A., Pallares J., Sorolla A., Domingo M., Santacana M., Gonzalez-Tallada FJ., Matias-Guiu X., Dolcet X. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Jan 11. [Epub ahead of print]

Tarragona J., Llecha N., Santacana M., Lopez S., Gatius S., Llobet D., Dolcet X., Palomar-Asenjo V., Gonzalez-Tallada FJ., Matias-Guiu X.DcR1 expression in endometrial carcinomas. Virchows Arch. 2010 456:39-44

Santacana M., Pallares J., Yeramian A., Llobet D., Dolcet X., Eritja N., Matias-Guiu X., Immunohistochemical features of Endometrial Carcinoma in Postradiation reccurrences. (in preparation

Yeramian A., Eritja N., Santacana M., Dolcet X., Matias-Guiu X. Both classical and alternative NF-κB pathways confer apoptosis resistance under hypoxia, in endometrial carcinoma (in preparation).

Eritja N., Llobet D., Domingo M., Yeramian A., Matias-Guiu X., Dolcet X: A novel 3D culture system of polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol (in press)

Llobet D., Eritja N., Santacana M., Pallares J., Macià A.,Yeramian A., Encinas M., Moreno-Bueno G., Palacios J., Lewis RE., Matias-Guiu X., Dolcet X. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and death receptor-induced apoptosis. (in preparation).

Moreno-Bueno G., Sanchez-Estevez C., Palacios J., Hardisson D., Shiozawa T. Low frequency of BRAF mutations in endometrial and in cervical carcinomas. Clin Cancer Res 2006; 12, 3865-3866.

Moreno-Bueno G., Fernandez PJ., Collado M., Tendero MJ., Rodriguez-Pinilla SM., Garcia-Cao I., Hardisson D., Diaz-Meco MT., Moscat J., Serrano M., Palacios J. Inactivation of the candidate tumor suppressor Par-4 in endometrial cancer. Cancer Res 2007 ; 67: 1927-1934

Moreno-Bueno G., Matías-Guiu X., Palacios J. Gene expression profiles associated to progression in endometrioid endometrial carcinoma (in preparation).

Moreno-Bueno G., Matías-Guiu X., Palacios J. Differences in gene expression profile betwen endometrioid endometrial carcinoma and endometrial carcinosarcomas (in preparation).

Castilla MA., Moreno-Bueno G., Romero L., Bischuola M., Cano A., Matías-Guiu X., Oliva E., Palacios J. miRNA signature of epithelial to mesenchymal transition in endometrial carcinosarcoma (in preparation).

Pallares J., Santacana M., Puente S., Lopez S., Yeramian A., Eritja N., Sorolla A., Llobet D., Dolcet X., Matias-Guiu X. A pplications of the tissue microarray technology in understanding the molecular features of endometrial carcinoma. A review. Anal Quant Cytol 2009 31:217-26 (reviews)

Ortega E., Marti RM., Yeramian A., Sorolla A., Dolcet X., Llobet D., Abal L., Santacana M., Pallares J., Llombart-Cussac A., Matias-Guiu X. Target therapies in gynaecologic cancers and melanoma. Sem Diagn Pathol 2008 25;262-273 (reviews)

Llobet D., Pallares J., Yeramian A., Santacana M., Eritja N., Velasco A., Dolcet X., Matias-Guiu X. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical view points. J Clin Pathol 2009 62:777-85 (reviews)

Velasco A., Pallares J., Santacana M., Yeramian A., Dolcet X., Eritja N., Puente S., Sorolla A., Llecha N., Matias-Guiu X. Loss of heterozigosity in endometrial carcinoma. Int J Gynecol Pathol 2008 27:305-17 (reviews)

Dra Pilar Navarro Medrano

Abasolo I., Pujal J., Rabanal RM., Serafin A., Navarro P., Millán O., Real FX. FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours. Eur J Nucl Med Mol Imaging. 36(7):1156-66. (2009)

Roda O., Ortiz-Zapater E., Martínez-Bosch N., Gutiérrez-Gallego R,. Vila-Perelló M., Ampurdanés C., Gabius HJ., André S., Andreu D., Real FX., Navarro P. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology. 136(4):1379-1390. (2009).

Hernández-Muñoz I., Skoudy A., Real FX., Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signalling pathways and stroma contribution. Pancreatology, 8:462-469. (2008)

Piqué M., López, JM.,. Foissac S., Guigó R., Méndez. R. A combinatorial code for CPE-mediated translational control .Cell, 132(3):434-448. (2008)

Belloc E., Méndez R. A deadenylation negative feedback mechanism governs meiotic metaphase arrest. Nature, 452(7190):1017-21 (2008)

Elíscovich C., Peset I., Vernos I., Méndez R..Localized CPE-mediated translation controls meiotic chromosome segregation. Nature Cell Biology, 10(7):858-865. (2008).

Belloc E., Piqué M., Méndez R. Sequential waves of polyadenylation and deadenylation define a translation circuit that drives meiotic progression. Biochemical Society Transactions, 36(Pt 4):665-670, (2008).

Dra Rosanna Paciucci Barzanti

Santamaría A., Castellanos E., Gómez V,. Benedit P., Renau-Piqueras J., Reventós J., Morote J., Thomson T., Paciucci R. PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol Cell Biol, 2005;25:1900-1911.

Morote J., Fernández S., Alaña L., Iglesias C., Planas J., Reventós J., Ramón y Cajal S., de Torres I., Paciucci R. PTOV1 Expression Predicts Prostate Cancer in Men with Isolated High-Grade Prostatic Intraepithelial Neoplasia in Needle Biopsy Clinical Cancer Research, 2008;14(9)2617-2622.

Paciucci R. Regulation of Aurora B kinase by the lipid raft protein Flotillin-1. (submitted, under revision, 2009)

Paciucci R. Flotillin-1 regulates Notch intracellular transport and transcriptional activity. (in preparation)

Paciucci R. Prostate Tumor Overexpressed 1 (PTOV1) is a novel repressor of Notch activity in prostate cancer. (in preparation)

Paciucci R Prostate Tumor Overexpressed 1 (PTOV1) overexpression in human epithelial tumors: a new marker associated to high grade malignant tumors. (in preparation)

Díaz VM., Hurtado M., Kort EJ., Resnati M., Blasi F., Thomson T., Paciucci R. Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells. Experimental Cell Research; 2006;312:2203-2213.

Hurtado M., Lozano JJ., Castellanos E., López-Fernandez L., Harshman K,. Martinez-A C., Ortiz A., Thomson T., Paciucci R. Activation of the epidermal growth factor signaling pathway by tissue plasminogen activator in pancreas cancer cells. Gut 2007;56;1266-1274

Dr Manuel Palacin Prieto

Dra Maria Antonia Lizarbe Iracheta

Dr Joaquin Abian Moñux

Fort J., de la Ballina LR., Burghardt HE., Ferrer-Costa C., Turnay J., Ferrer-Orta C., Usón I., Zorzano A., Fernández-Recio J., Orozco M., Lizarbe MA., Fita I., Palacín M. The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane. J Biol Chem. 2007 Oct 26;282(43):31444-52.

Turnay J., Fort J., Olmo N., Santiago-Gómez A., Palacín M., Lizarbe MA. Spectroscopic and structural characterization human 4F2hc ectodomain. Insights into protein folding/unfolding mechanism. (submitted)

Dr Santiago Ramon y Cajal

Lleonart ME., Vidal F., Gallardo D., Diaz-Fuertes M., Rojo F., Cuatrecasas M., López-Vicente L., Kondoh H., Blanco C., Carnero A., Ramón y Cajal S. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncology Reports 16(3):603-8. (2006)

Castellví J., Garcia A., Rojo F., Ruiz-Marcellan C., Gil A., Baselga J., Ramon y Cajal S. Identification of phospho 4EBP1 as a hallmark of cell signaling pathway that associates with survival in ovarian cancer. Cancer 107(8):1801-11. (2006)

Ramón y Cajal S., Rojo F., Pons B., Cuatrecasas M., Castellví J., Iglesias C., Armengol G. Targeting protein translation in human tumors. P-4EBP1 as a key clinical-molecular factor.) AACR annual meeting education book. (2007)

Rojo F., Najera L., Lirola J., Jimenez J., Guzman M., Sabadell MD., Baselga J., Ramon y Cajal S. 4E-binding protein 1,a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. Jan 1;13(1):81-9. (2007)

Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. Apr 18;99(8):628-38. (2007)

Abal M., Llaurado M., Doll A., Monge M., Colas E., Gonzalez M., Rigau M., Alazzouzi H., Demajo S., Castellvi J., Garcia A., Ramon y Cajal S., Xercavins J., Vazquez-Levin MH., Alameda F., Gil-Moreno A., Reventos J. Molecular determinants of invasion in endometrial cancer. Clin Transl Oncol. May;9(5):272-7. (2007)

Armengol G., Rojo F., Castellví J., Iglesias C., Cuatrecasas M., Pons B., Baselga J., Ramón y Cajal S. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res. (2007) Aug 15;67(16):7551-5.

Guijarro MV., Leal JF., Fominaya J., Blanco-Aparicio C., Alonso S., Lleonart M., Castellvi J., Ruiz L., Ramon y Cajal S., Carnero A. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. Aug;28(8):1646-52. (2007)

Guijarro MV., Leal JF., Blanco-Aparicio C., Alonso S., Fominaya J., Lleonart M., Castellvi J., Ramon y Cajal S., Carnero A. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis. Oct;28(10):2096-104. (2007)

Leal JF., Fominaya J., Cascón A., Guijarro MV., Blanco-Aparicio C., Lleonart M., Castro ME., Ramon y Cajal S., Robledo M., Beach DH., Carnero A. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene. 27(14);1961-70. (2008)

Castro ME., Leal JF., Lleonart ME., Ramon y Cajal S., Carnero A. Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis. 29(7); 1343-50. (2008)

Leal J., Ferrer I., Blanco-Aparicio C., Hernández-Losa J., Ramón y Cajal S., Carnero A., Lleonart M. S-Adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis. 29(11); 2089-952 (2008)

López-Vicente L., Armengol G., Pons B., Coch L., Argelaguet E., Lleonart M., Hernández-Losa J., De Torres I., Ramon y Cajal S. Regulation of replicative and stress-induced senescence by RSK4, which is downregulated in human tumors. Clinical Cancer Research Jul 15;15(14):4546-53 (2009)

Castellvi J., Garcia A., Ruiz-Marcellan C., Hernández-Losa J., Peg V., Salcedo M., Gil-Moreno A., Ramon y Cajal S. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol. Oct;40(10):1418-26 (2009)

Benavente S., Vergés R., Hermosilla E., Fumanal V., Casanova N., García A., Ramón y Cajal S., Giralt J. Overexpression of Phosphorylated 4E-BP1 Predicts for Tumor Recurrence and Reduced Survival in Cervical Carcinoma Treated with Postoperative Radiotherapy. Int J Radiat Oncol Biol Phys. Apr 11. (2009)

Dr Juan Carlos Rodríguez-Manzaneque

Rodríguez-Manzaneque JC., Carpizo O., Plaza-Calonge MC., Torres-Collado AX., N.-M S., Simons TM, Horowitz A., Iruela Arispe ML. Cleavage of Syndecan-4 by AOAMTS1 affects cell adhesion and migration. J Biol Chem (M8-01432)

Rodríguez-Manzaneque JC., Carpizo D., Plaza-Calonge MD., Torres-Collado AX., Thai SN., Simons M,. Horowitz A., Iruela-Arispe ML. Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol. Apr;41(4):800-10 (2009)

Casal C., Torres-Collado AX., Plaza Calonge MC., Martino-Echarri E., Ramón y Cajal S., Rojo F., Griffioen AW., Rodríguez-Manzaneque JC. ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells. Cancer Research (2nd review)

Dr Carlos Saura Antolin

Rocher-Ros V., España J., Saura CA. Presenilin regulates EGF receptor-mediated signalling. X International Conference on Alzheimer’s Disease and Related Disorders Madrid, July 2006. Alzheimer´s & Dementia, Vol 2 (3) p S497. (2006)

Rocher-Ros V., Mao J-H., Gines S., Metzger D., Chambon P., Balmain P., Saura CA. Presenilin regulates EGFR signaling and cell transformation through the ubiquitin ligase Fbw7. Oncogene. (2010) (in press)

Rocher-Ros V., Aznar-Benitah S., Saura CA. Presenilin acts as a dose-dependent tumor suppressor gene in the skin. (2010) (in preparation)

Saura CA. Presenilins/g-secretase and inflammation. Frontiers Aging Neuroscience. (2010) (in press)

Dr Francesc Solé Ristol

Solé F. Malignant Lymphomas Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma. Haematologica;91:1289-1291 (2006

Baró C., Salido M., Domingo A., Granada I., Colomo L., Serrano S., Solé F.. Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma. Haematologica.; 91: 1289-1291. (2006)

Baró C., Salido M., Espinet B., Astier L., Domingo A., Granada I., Millà F., Carrió A., Costa D., Luño E., Hernández JM., Campo E., Florensa L., Ferrer A., Salar A., Bellosillo B., Besses C., Serrano S., Solé F. New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by spectral karyotyping (SKY). Leuk Res; 32: 727-736. (2008)

Espinet B., Bellosillo B., Melero C., Vela MC., Pedro C., Salido M., Pijuan L., Florensa L., Besses C., Serrano S., Solé F. FISH is better than BIOMED-2 to detect IGH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. Leuk Res; 32: 737-742. (2008)

Baró C., Espinet B., Salido M., Colomo L., Luño E., Florensa L., Ferrer A., Salar A., Campo E., Serrano S., Solé F. FOXP1 is not rearranged in splenic marginal zone lymphoma.. Histology and Histopathology. (accepted)

Baró C., Espinet B., Salido M., Garcia M., Sanchez B., Florensa L., Serrano S., Solé F. Cryptic IGH/BCL2 rearrangement with variant FISH patterns in Follicular lymphoma. Human Pathology

Dr Timothy Thomson Okatsu

Dr Pedro Luis Fernández Ruiz

Dr Santos Mañes Brotón

Bermudo R., Abia D., Ferrer B., Nayach I., Benguria A., Zaballos A., del Rey J., Lozano J., Miró R., Campo E., Martínez-Alonso C., Ortiz AR., Fernández PL., and Thomson TM. Transcriptional protiling of prostate cancer reveals a 7-gene signature diagnostic ot malignancy and a novel chromosomal gain on 17q25.3. Mod Pathol (under review)

Bermudo R., Abia D., Ferrer B., Nayach I., Benguria A., Zaballos A., Del Rey J., Miró R., Campo E., Martínez-Alonso C., Ortiz AR., Fernández PL.,and Thomson TM. Transcriptional profiling reveals a 7-gene signatura for robust discrimination of tumor and normal prostate tissue, and a novel chromosomal gain on 17q25.3. XI Meeting ASEICA, May 10-12, Las Palmas de Gran Canaria. Clin Tranl Oncol 9:48, P191.

Bermudo R., Abia D., Ferrer B., Nayach I., Benguria A., Zaballos A., del Rey J., Lozano JJ., Miró R., Campo E., Martínez-Alonso C., Ortiz AR., Fernández PL., Thomson TM. Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. BMC Cancer; 8:315 (2008)

Soler M., Mancini F., Meca-Cortés O., Sánchez-Cid L., Rubio N., López-Fernández S., Lozano JJ., Blanco J., Fernández PL.,Thomson TM. HER3 is required for the maintenance of neuregulin–dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer; 125:2565-75 (2009)

Celià T., Meca-Cortés O., Martínez de la Paz A., Rubio N., Arnal A., Sánchez-Cid L., Estarás C., Lozano JJ., Martínez-Balbás M., Molà J., Vilella R., Gomis R., Fernández PL., Blanco J., Thomson TM. Mesenchymal reprogramming driven by interaction between clonal tumor subpopulations. (in preparation)

Morente M., Fernández PL., de Álava E. Biobanking: old activity or young discipline? Semin Diagnost Pathol 25:317-22. (2008)

Mozos A., Sole M., Miquel R.,Petit P., Nadal A.,Fernandez PL.Usefulness and limitations of Alpha-Methylacyl-CoA Racemase expression in the hepatobiliary system and pancreas: a wide tissue microarray analysis of normal and neoplastic epithelia. Anal Quant Cytol. (in press)

Bermudo R., Abia D., Mozos A., García E., Alcaraz A., Ortiz AR., Thomson TM., Fernández PL. Haystack in a needle: recycling biopsy needles for sensitive molecular diagnosis of prostate cancer. (in preparation)

Mejías R., Costo R., Roca AG., Arias CF., Veintemillas-Verdaguer S., González-Carreño T., del Puerto Morales M., Serna CJ., Mañes S., Barber DF. Cytokine adsorption/release on uniform magnetic nanoparticles for localized drug delivery. J Control Release. 130:168-174. (2008)

Mira E., Leon B, Barber DF., Jimenez-Baranda S., Goya I., Almonacid L., Marquez G., Zaballos A., Martınez-A. C., Stein JV., Ardavin C., Mañes S. Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway. J Immunol, 2008; 181:3524-3534.

Mira E., Mañes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr. Metab. Immune Disord Drug Targets.; 9:237-247 (2009)

Mejias R., Pérez-Yagüe S., Roca AG., Pérez N., Villanueva A., Cañete M., Mañes S., Ruiz-Cabello J., Benito M., Labarta A., Batlle X., Veintemillas-Verdaguer S., Puerto-Morales M., Barber DF., Serna CJ. Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles. Nanomedicine. (2010) (in press).

Caffarel MM., Andradas C., Mira E., Cerutti C., Flores JM., García-Real I., Mañes S., Guzmán M., Sánchez C. Antitumoral effect of cannabinoids in a genetic model of breast cancer. (submitted.)

Tardáguila M., Mira E., González-Martín A., Lira SA., Mateo F., Garcia S., Thomson TM., Mañes S. CX3CL1 induces epithelial-to-mesenchymal transition in vitro and enhances local tumor invasiveness in vivo. (in preparation)

Dr Laura Tusell Padrós

Genescà A., Martin M., Latre L., Soler D., Pampalona J., Tusell L. Telomere dysfunction: a new player in radiation sensitivity. BioEssays 28: 1172-1180, (2006)

Tusell L., Soler D., Agostini M., Pampalona J., Genescà A. The Number of Dysfunctional Telomeres in a Cell: One Amplifies; More than One Translocate. Cytogenetics and Genome Research 122:315-325, (2008)

Soler D., Pampalona J., Tusell L., Genescà A. Radiation Sensitivity increases with proliferation-associated telomere dysfunction in nontransformed human epithelial cells. Aging Cell 8:414-425, (2009)

Pampalona J., Soler D., Genescà A., Tusell L. Telomere dysfunction and chromosome structure modulate the contribution of individual chromosomes in abnormal nuclear morphologies. Mutation Research 683:16-22, (2010)

Pampalona J., Soler D., Genescà A., Tusell L. Whole chromosome loss is promoted by telomere dysfunction in primary cells. Genes. Chromosomes & Cancer 49:368-378, (2010)

Soler D., Pampalona J., Ribas M., Tusell L., Genescà A. Los telómeros, un nuevo factor modulador de la radiosensibilidad celular. Avances en Radiobiología. CIEMAT, Madrid (pp.71-87) (2007)

Tusell L., Soler D., Martín M., Latre L., Pampalona J., Terradas M., Genescà A. Chapter 2: When chromosomes become uncapped: Telomere dysfunction-driven chromosomal instability in carcinogenesis En: Multiple pathways in cancer development Transworld Research Network, Kerala (pp.27-42) (2008)

Dr Francesc Viñals Canals

Dr Francisco Javier García del Muro Solans

Castillo-Ávila W., Piulats JM., Garcia del Muro FX., Vidal A., Condom E., Casanovas O., Mora F., Germa JR., Capellà G., Villanueva A., Viñals F. Sunitinib blocks tumor growth on an orthotopic model of human testicular germ cell tumor through both its anti-angiogenic and direct anti-tumor effects. Clinical Cancer Research (submited)

Garcia del Muro FX., Maroto P., Guma J., Sastre J., López Brea M., Arranz JA., Lainez N., Soto de Prado D., Aparido J., Piulats JM., Pérez X., Germá-Lluch JR. Chemotherapv as an alternative to radiotherapv in the treatment of stage IIA/S testicular seminoma: A Spanish Germ Cell Cancer Group Studv. J Clin Oncol (in press)

Piulats JM., Martinez-Iniesta M., August Vidal A., Mora J., Figueras A., Nadal M., Padullés L., Aytés A., Mollevi DG., Puertas S., Gallegos M., Nadal E., Muñoz P., González S., Castillo W., Algaba F., Condom E., Viñals F., Germa JR., Capella G., Garcia de Muro X., Villanueva A. Nude mice model of primarv human nonseminoma germ cell tumors mimic clinical and cisplatin-chemotherapv tumor behavior. (finishing redaction).

Piulats JM., Garcia del Muro FX., Huddart R., Aparido J., Pazares L., Sanehez M., Olmos D., Vidal A., Villanueva A., Garda M., Germa JR. Phase 11 multicenter studv of imatinib in patients with chemorefractorv germ cell tumors that Express e-kit. (finishing redaction)

Castillo-Ávila W., Piulats JM, Garcia del Muro X., Vidal A., Condom E., Casanovas O, Mora J., Germà JR., Capellà G., Villanueva A., Viñals F.. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and resistant human testicular germ cell tumors. Clinical Cancer Research 15: 3384-3395, (2009).